News Breaks |
|
|
| September 28, 2012 |
| 07:51 EDT |  | JAZZ, QCOR | Jazz Pharmaceuticals Xyrem very different from Acthar, says Oppenheimer
After meeting with Jazz's management, Oppenheiemr believes that investors are drawing "inappropriate parallels" between Jazz's Xyrem and Questcor's (QCOR) Acthar drug. The firm believes that concerns over Xyrem pricing are unwarranted and it maintains a $66 target and Outperform rating on Jazz. |
|
|
News For JAZZ;QCOR From The Last 14 Days Check below for free stories on JAZZ;QCOR the last two weeks. |
|
|
| May 15, 2013 |
| 11:20 EDT |  | QCOR | Options with increasing implied volatility: QCOR MYGN GDI
 Subscribe for More Information |
|
| 05:57 EDT | | QCOR | Stocks with implied volatility movement; SODA QCOR
Subscribe for More Information |
|
| May 8, 2013 |
| 13:07 EDT |  | JAZZ | Jazz sinks after CEO comment sparks generic concern
Jazz Pharmaceuticals (JAZZ) is retreating, after the company's CEO made a comment that led to speculation that a generic version of its narcolepsy treatment could be launched. WHAT'S NEW: The FDA may modify the rules governing Jazz's narcolepsy treatment, Xyrem, to allow more than one pharmacy to distribute the drug, Jazz CEO Bruce Cozadd stated during the company's first quarter results conference call last night. In a note today to investors, Piper analyst David Amsellem wrote that the CEO's statement could increase investors' anxiety regarding the possible introduction of generic versions of Xyrem. However, Jazz's patents, not FDA rules, are the main hurdles preventing generic versions of Xyrem from being launched, Amsellem stated. The analyst continues to believe that Jazz will either win the patent infringement case it has filed against Roxane Laboratories, which is trying to market a generic version of Xyrem, or reach a settlement with generic manufacturers that will prevent them from marketing a generic version of Xyrem until 2019. One of Jazz’s patents for Xyrem will expire in that year, the analyst noted. He maintained a $69 price target and Overweight rating on Jazz. TODAY'S PRICE ACTION: In early afternoon trading, Jazz slumped $5.60, or 9.5%, to $53.90. |
|
| 12:16 EDT | | JAZZ | Jazz Pharmaceuticals weakness a buying opportunity, says Guggenheim
|
|
| May 7, 2013 |
| 16:37 EDT |  | JAZZ | Jazz Pharmaceuticals sees FY13 adjusted EPS $6.10-$6.30, consensus $5.87
Subscribe for More Information |
|
| 16:35 EDT | | JAZZ | Jazz Pharmaceuticals announces up to $200M share repurchase program
Subscribe for More Information |
|
| 16:35 EDT | | JAZZ | Jazz Pharmaceuticals reports Q1 adjusted EPS $1.37, consensus $1.35
Subscribe for More Information |
|
| 12:53 EDT | | QCOR | Options with decreasing implied volatility: QCOR BMC FOSL TPX LNKD
Subscribe for More Information |
|
| 05:55 EDT | | QCOR | Stocks with implied volatility movement; QCOR GRPN
Stocks with implied volatility movement; Questcor (QCOR), Groupon (GRPN) according to iVolatility. |
|
| May 6, 2013 |
| 12:00 EDT | | QCOR | Options with decreasing implied volatility: RVBD UNXL FIRE QCOR EBIX
Subscribe for More Information |
| |
|
|
|
|
